Spero Therapeutics (SPRO) 10-Q2023 Q1 Quarterly report

Filed: 11 May 23, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: downturn, examination, FASB, feasible, judgement, largest, length, overhead, PBM, prudent, TCJA, tranched, vaccination, vaccine

Removed: accelerated, acceptability, acute, afflicted, Aid, amendment, anticompetitive, AP, assumption, beneficially, CAI, Canadian, carryback, cessation, choose, circumstance, classification, collateral, combat, complying, concentration, conditional, contact, declaration, deduct, deducting, deduction, defer, desire, discussed, distancing, domestic, economy, emerge, emergency, emerging, enrolling, entrench, evergreen, explanatory, foregoing, full, geographic, golden, HCR, herewith, holder, home, imputed, Innovation, Inspectional, intention, interactive, irrevocably, Jumpstart, maturity, mission, mutual, NOL, nonbinding, nonconvertible, novate, occurring, omicron, orally, originating, outlined, pace, paper, parachute, paragraph, passage, pediatric, pertaining, postpone, postponed, preapproval, predicted, prevalence, prioritization, quarantine, ranging, rapid, realization, reclassification, recommended, recovering, refocusing, refund, regular, release, remeasure, remote, repayment, representing, Resiliency, resume, resuming, resumption, revise, revised, Roadmap, routine, SBIR, Secretary, sequester, serving, shareholder, situation, strain, submitted, sum, surfaced, takeover, temporarily, thereon, transit, treating, Trump, twelve, underlying, variant, vote, withdrawing, Wuhan

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated SPRO transcripts

SPRO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Spero Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended March 31, 2023 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: May 11, 2023	/s/ Ankit Mahadevia, M.D.
	Ankit Mahadevia, M.D.
	President and Chief Executive Officer
	(Principal Executive Officer)


Dated: May 11, 2023	/s/ Satyavrat Shukla
	Satyavrat Shukla
	Chief Financial Officer and Treasurer
	(Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.